Celldex Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celldex Therapeutics, Inc.
Plus deals involving Dong-A/Polifarma, Intas/Syna, Kissei/Synmosa, Ono/Memo, Takeda/Shionogi, Fosun/Lilly and JW Therapeutics/2seventy bio.
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
The small-cap biotech is not currently favored by investors but CEO Anat Cohen-Dayag tells Scrip she believes Compugen could have the optimal TIGIT strategy.
Analysts are keen to know more about the statistical weighting of Roche’s SKYSCRAPER 1 study of the TIGIT inhibitor, while Merck & Co can learn from their rival’s slip-up for their own trial design.
- Large Molecule
- Other Names / Subsidiaries
- Avant Immunotherapeutics, Inc.
- CuraGen Corporation
- Kolltan Pharmaceuticals, Inc.
- Xetrios Therapeutics Inc.